The relationship between lipocalin-2 and free testosterone levels in polycystic ovary syndrome
Abstract
Introduction: Lipocalin-2 is an adipokine that is mainly produced from adipocytes and macrophages. Data related to PCOS and other obesity-associated disorders have shown divergent results. Here, we studied lipocalin-2 concentrations in women with PCOS and in healthy women, and investigated the potential contributors underlying lipocalin association with PCOS.
Material and methods: Forty-four women with PCOS and 47 age- and BMI-matched healthy women were enrolled. Fasting serum glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), and free testosterone levels were measured. The body fat percentage was measured by bioelectrical impedance.
Results: Lipocalin-2 concentrations were significantly higher in the PCOS group than in the control group (55.74 ± 17.54 ng/mL vs. 36.46 ± 19.62 ng/mL, p = 0.011). There was a correlation between lipocalin-2 levels and free testosterone. In a multiple regression model, the body fat percentage, HOMA-IR, and hs-CRP were not associated with lipocalin-2. However, only free testosterone was associated with lipocalin-2. A “lipocalin-2 = 11.214 + (1.943 × free-testosterone)” equation was obtained.
Conclusions: Serum lipocalin-2 levels were higher in women with PCOS, and only free testosterone was associated with lipocalin-2. Lipocalin-2 levels and their influencing factors have discrepant results in both PCOS and other obesity- or insulin resistance-related metabolic disorders. Thus, the potential role of lipocalin-2 in PCOS should be clarified. (Endokrynol Pol 2017; 68 (1): 7–12)
Keywords: 1-PCOS2- lipocalin-23- free testosterone
References
- Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85(7): 2434–2438.
- Kozakowski J, Jeske W, Zgliczyński W, et al. Body composition, glucose metabolism markers and serum androgens - association in women with polycystic ovary syndrome. Endokrynol Pol. 2013; 64(2): 94–100.
- Diamanti-Kandarakis E, Livadas S, Kandarakis SA, et al. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol. 2008; 158(4): 525–531.
- Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(4): 1929–1935.
- Kruszyńska A, Słowińska-Srzednicka J, Jeske W, et al. Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment. Endokrynol Pol. 2014; 65(1): 2–10.
- Panidis D, Tziomalos K, Koiou E, et al. The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reprod Biol Endocrinol. 2010; 8: 151.
- Wang Yu, Lam KSL, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007; 53(1): 34–41.
- Esteve E, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009; 32 Suppl 2: S362–S367.
- van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem. 2007; 53(1): 5–7.
- Gencer M, Gazi E, Hacıvelioğlu S, et al. The relationship between subclinical cardiovascular disease and lipocalin-2 levels in women with PCOS. Eur J Obstet Gynecol Reprod Biol. 2014; 181: 99–103.
- Koiou E, Tziomalos K, Katsikis I, et al. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2012; 28(1): 20–24.
- Cakal E, Ozkaya M, Engin-Ustun Y, et al. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. J Endocrinol Invest. 2011; 34(2): 97–100.
- Stejskal D, Karpísek M, Humenanska V, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008; 40(6): 381–385.
- Zhang J, Wu Y, Zhang Y, et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008; 22(6): 1416–1426.
- Guo H, Zhang Y, Brockman DA, et al. Lipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female mice. Endocrinology. 2012; 153(3): 1183–1193.
- Fried SK, Greenberg AS. Lipocalin 2: a "sexy" adipokine that regulates 17β-estradiol and obesity. Endocrinology. 2012; 153(4): 1582–1584.
- Luque-Ramírez M, Martínez-García MÁ, Montes-Nieto R, et al. Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum Reprod. 2013; 28(7): 1908–1918.
- Martínez-García MÁ, Montes-Nieto R, Fernández-Durán E, et al. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013; 98(2): E388–E396.
- Legro RS, Arslanian SA, Ehrmann DA, et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12): 4565–4592.
- Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29(4): 791–801.
- Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
- Jang Y, Lee JHo, Wang Yu, et al. Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome. Clin Exp Pharmacol Physiol. 2012; 39(2): 194–199.
- De la Chesnaye E, Manuel-Apolinar L, Zarate A, et al. Lipocalin-2 plasmatic levels are reduced in patients with long-term type 2 diabetes mellitus. Int J Clin Exp Med. 2015; 8(2): 2853–2859.
- Wallenius V, Elias E, Bergstrom GML, et al. The lipocalins retinol-binding protein-4, lipocalin-2 and lipocalin-type prostaglandin D2-synthase correlate with markers of inflammatory activity, alcohol intake and blood lipids, but not with insulin sensitivity in metabolically healthy 58-year-old Swedish men. Exp Clin Endocrinol Diabetes. 2011; 119(2): 75–80.
- Guo H, Jin D, Zhang Y, et al. Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes. 2010; 59(6): 1376–1385.
- Choi KM, Kim TN, Yoo HJ, et al. Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf). 2009; 70(4): 569–574.
- Moghadasi M, Mohammadi Domieh A. Effects of Resistance versus Endurance Training on Plasma Lipocalin-2 in Young Men. Asian J Sports Med. 2014; 5(2): 108–114.
- Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology. 2000; 52(5): 595–600.
- Nantermet PV, Xu J, Yu Y, et al. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem. 2004; 279(2): 1310–1322.
- Asirvatham AJ, Schmidt M, Gao B, et al. Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology. 2006; 147(1): 257–271.
